CAMBRIDGE, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

CAMBRIDGE, Mass. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

Following successful FDA meeting, the Company plans to initiate UPLIFT, a single-arm registrational strategy to evaluate XMT-1536 in platinum-resistant ovarian cancer, in Q1 2021 Data from the ovarian cancer expansion cohort of the XMT-1536 Phase 1 study continued to show consistent activity and